Houbouyan L, Padilla A, Gray E, Longstaff C, Barrowcliffe T W
Hopital Ambroise-Paré, Boulogne, France.
Blood Coagul Fibrinolysis. 1996 Jan;7(1):24-30. doi: 10.1097/00001721-199601000-00003.
Inhibition of thrombin generation by heparin and low-molecular-weight (LMW) heparins is an important parameter which relates to their anticoagulant actions in vivo. Previous studies in our laboratory used a clotting assay for assessment of thrombin generation but other published studies have used a chromogenic method. We have therefore measured the inhibition of thrombin generation by unfractionated heparin (UFH) and LMW heparins by a modified chromogenic method using microtitre plates and compared the results with the clotting method. The degree of inhibition of thrombin generation when calculated from both peak thrombin concentrations and areas under the curve in the chromogenic assay was the same. When the activities of each heparin were expressed as EC80, i.e. concentrations required for 80% inhibition of thrombin generation, the EC80 were higher in the chromogenic assay than in the clotting system. However when the potencies of the LMW heparins were expressed as percentages of that of the UFH standard by parallel line analysis, the differences between clotting and chromogenic assay results were small and not statistically significant (P > 0.05). This study demonstrates the feasibility of measuring inhibition of thrombin generation by a modified chromogenic method using microtitre plates, and shows that the results with this method are similar to those obtained with the clotting method.
肝素和低分子量(LMW)肝素对凝血酶生成的抑制作用是一个重要参数,它与它们在体内的抗凝作用相关。我们实验室之前的研究使用凝血试验来评估凝血酶生成,但其他已发表的研究使用的是显色法。因此,我们采用改良的显色法,利用微量滴定板测定了普通肝素(UFH)和低分子量肝素对凝血酶生成的抑制作用,并将结果与凝血法进行了比较。在显色试验中,根据凝血酶峰值浓度和曲线下面积计算得出的凝血酶生成抑制程度是相同的。当将每种肝素的活性表示为EC80,即抑制80%凝血酶生成所需的浓度时,显色试验中的EC80高于凝血系统中的EC80。然而,当通过平行线分析将低分子量肝素的效价表示为UFH标准品效价的百分比时,凝血试验和显色试验结果之间的差异很小,且无统计学意义(P>0.05)。本研究证明了使用微量滴定板通过改良显色法测量凝血酶生成抑制作用的可行性,并表明该方法的结果与凝血法获得的结果相似。